The pharmaceutical sector demonstrated robust performance in Q1 FY27, with multiple companies reporting strong results. Divi's Laboratories hit a 52-week high with 27.8% topline growth and operating margins expanding from 30% in June 2025 to 41%. Ajanta Pharma recorded strong net sales growth largely driven by a 57% increase in US generics business aided by two new launches. Lupin crossed the ₹8,000 crore quarterly revenue mark for the first time with robust US revenue growth, securing six new approvals and launching 3 new products during the quarter. Gufic Biosciences reported exceptional profit growth with 85.5% year-over-year increase in profit after tax to ₹22.0 crore, substantially outpacing revenue growth of 14.9% as the company gains operating leverage from its new capacity.
Shares of Alkem Laboratories gained 2.00% to trade at ₹5,481.50 in Tuesday's session, placing it among the notable gainers on the Nifty Midcap 150 index. According to reports from Moneycontrol, the stock continues to maintain its position as a notable entity in the midcap segment, supported by strong financial performance and consistent corporate actions. The broader Nifty Pharma index has shown resilience with Sun Pharma exerting a disproportionate pull with its 21.34% representation and YTD returns exceeding 14%. Gufic Biosciences stock was trading at ₹418.2, down 0.95% from the previous close, but remains well above its 52-week low of ₹268 and near its 52-week high of ₹448.
The company's consolidated revenue for the quarter-ending June 2026 stood at ₹3,740.15 crore, showing an increase from ₹3,371.14 crore in June 2025. As reported by Moneycontrol, net profit also demonstrated significant improvement, reaching ₹521.49 crore in June 2026, compared to ₹251.68 crore in the quarter-ending March 2026. The company's EPS for the quarter was ₹43.49. Gufic Biosciences delivered broad-based financial improvement with total revenue reaching ₹260.8 crore, up from ₹226.9 crore in Q1 FY2026 and ₹252.1 crore in the previous quarter. EBITDA increased 42.2% year-over-year to ₹47.2 crore, lifting the EBITDA margin to 18.09% from 14.60% in the prior-year quarter—a 349 basis point improvement.
For the year-ending March 2026, Alkem Laboratories reported consolidated revenue of ₹14,712.27 crore, a substantial increase from ₹12,964.52 crore in the previous year. According to the financial data, net profit for the same period rose to ₹2,353.13 crore from ₹2,216.00 crore. The company's EPS reached ₹192.51 in March 2026, while the Return on Equity stood at 16.65%. Gufic Biosciences management indicated that FY2027 revenue is expected to reach ₹1,100 crore, representing 15-20% growth as a "bare minimum commitment," with ambitions to exceed that level as multiple growth initiatives gain traction.
The company has declared several dividends to shareholders. As reported by Moneycontrol, a final dividend of ₹10.00 per share (500%) was announced on May 29, 2026, with an effective date of August 07, 2026. Prior to this, an interim dividend of ₹43.00 per share (2150%) was announced on February 13, 2026, with an effective date of February 20, 2026.
Key financial ratios indicate a healthy financial position for Alkem Laboratories. According to the company's balance sheet, Total Assets stood at ₹20,872 crore as of March 2026, up from ₹17,691 crore in March 2025. The Debt to Equity ratio was maintained at a low 0.12, reflecting minimal leverage. The P/E ratio was 27.53 and P/B ratio was 4.59 as of March 2026.
